Key points GLP-1 drugs can transform the health of people with obesity, quiet food noise, and may level the weight-loss playing field. Research on the drugs mental health effects is mixed. Experts worry widespread use could fuel sizeism and eating disorders. Psychologists are helping GLP-1 patients develop healthy behaviors and manage body image, identity, and relationship changes.
How GLP-1 drugs like Ozempic quiet 'food noise' and change emotional eating patterns. What neuroimaging and behavioral research reveals about reward circuits, cravings, and building a healthier relationship with food.
Beyond improving glycemic control and promoting weight loss, GLP-1 RAs exert central actions relevant to mood disorders, including modulation of dopaminergic reward pathways, enhancement of hippocampal neurogenesis, attenuation of neuroinflammation, and regulation of appetite and energy balance.
Scientists in Japan followed 92 people with diabetes over their first year of taking GLP-1 receptor agonists and found that individuals with different eating patterns responded differently to the drugs.
Emerging evidence suggests they alter food cue reactivity, reward signaling, and addictive behaviors, while leaving key questions about mood and emotional eating unresolved.
In the present study we summarized the psychotropic beneficial effects and potential adverse effects of GLP-1RAs. Novel clinical and real-world studies may endorse the potential of GLP-1RAs in psychotropic disorders to improve mental health.
When exposed to negative emotions and then consuming food, emotional eaters perceive the food as tasting better, indicating their reward system reacts positively to food during stress. This process is similar to the dopamine release observed in drug addiction.
The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.
